An analysis of the influence of infection on overall survival rates, following modified posterior pelvic exenteration for advanced ovarian cancer

Abstract

Objectives:The aim of our study was to determine the association between the appearance of infection after modified posterior pelvic exenteration (MPE) and the time to adjuvant chemotherapy (TTC), and to examine whether infection has any impact on clinical results by delaying the start of chemotherapy. Material and methods:Our retrospective study analyzed 77 patients who had undergone MPE followed by adjuvant chemotherapy. Postoperatively, either there was no residual tumor or, the residual tumor was less than 2.5 mm, in 76.7% of the study patients. Our study group was divided into two subgroups for comparison; the first group consisted of 41 patients with postoperative infections, and the second group of 36 patients had no infections. The infections of the first group were monitored during a 90-day postoperative period. Median TTC and overall survival rates (OS) were determined for those patients who developed an infection as well as for those who did not. Results:The expected 5-year survival rate was 0.40 (SD = 0.09) for those patients without infection and 0.17 (SD = 0.07) for those patients with infection. The survival curves of patients with infection and those without infection were significantly different statistically (p = 0.038). The median TTC differed significantly for those patients who developed infection compared with those patients who did not develop infection (37 days compared with 27.5 days respectively, p = 0.024); and patients without infection were statistically more likely to receive chemotherapy within 25 days following surgery than in the subsequent 25-42-day period compared with those patients who did develop infection (p = 0.048). No statistically significant differences were found between the two groups in relation to results following the initiation of chemotherapy during the first 42 days postoperatively (p = 0.445). Conclusions:The absence of postoperative infection was associated with better survival rates. Patients with infection experienced a longer time interval between surgery and the start of chemotherapy, without negative impact to their overall survival rates.

Analysis of the treg cell population in the peripheral blood of ovarian cancer patients in relation to the long-term outcomes

“…Cancer surgery is necessary and life-saving; however, the majority of patients develop postoperative recurrence and metastases, which constitute the main causes of cancer-related deaths [32]. Rationally combining cancer surgery with immunotherapies can transform the immunosuppressive effect into a therapeutic opportunity [26].…”

The potential predictive value of serum srCaS1 levels for overall survival in endometrial cancer

“…Numerous studies have shown that tumor RCAS1 expression is an indicator of poor prognoses in patients with cancer [16,[24][25][26][27][28][29]. However, there is sparse data on serum sRCAS1 levels as a prognostic factor in human malignancies, and most of the data that does exist relates to the evaluation of short term outcomes [23].…”

“…However, there is sparse data on serum sRCAS1 levels as a prognostic factor in human malignancies, and most of the data that does exist relates to the evaluation of short term outcomes [23]. From a clinical point of view, the most informative prognostic factors are those that influence patients' overall survival (OS) [28,30]. To the best of our knowledge, there is no study evaluating the influence of serum sRCAS1 levels on the OS rates of patients with endometrial cancer.…”

High post‐treatment serum soluble receptor‐binding cancer antigen expressed on SiSo cells (sRCAS1) levels is associated with poor survival of patients with cervical cancer

“…However, these studies evaluated predominantly short-term outcomes or correlated sRCAS1 levels with other prognostic factors. 7,26,27 The main result of our study indicates the prognostic utility of serum sRCAS1 levels in patients with cervical cancer. We have shown that increased levels of posttreatment serum sRCAS1 were associated with shortened OS.…”

“…Only a few studies have focused on the prognostic significance of serum sRCAS1 levels in human neoplasms. However, these studies evaluated predominantly short‐term outcomes or correlated sRCAS1 levels with other prognostic factors . The main result of our study indicates the prognostic utility of serum sRCAS1 levels in patients with cervical cancer.…”